SANTA CRUZ BIOTECHNOLOGY, INC.

HL60 Antigen (IPO-M6): sc-59203

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Leukocytes, or white blood cells, are cells that form an important component of the blood. They are produced in the bone marrow and function as part of the immune system to defend the body against infectious disease and foreign materials, and they are also produced in abundance in the lymphatic system, the spleen and other body tissues. Leukocytes can be subclassified into several different types of cells, such as erythroid cells, which give rise to erythrocytes; macrophage subset cells, which are large leukocytes; endothelial cells, which express leukocyte-specific cell-adhesion molecules; and granulocytes, which can be further classified as either neutrophils, eosinophils or basophils. Leukemia is a cancer of the blood or bone marrow that usually leads to an abnormal proliferation of leukocytes. Specific antigens expressed on sets and subsets of leukocytes may aid in the identification of these types of cells. HL60 represents a human leukemia cell line useful in many research applications.

REFERENCES

1. Brown, G., et al. 2002. HL60 cells halted in G_1 or S phase differentiate normally. Exp. Cell Res. 281: 28-38.
2. Grebenová, D., et al. 2003. Mitochondrial and endoplasmic reticulum stress-induced apoptotic pathways are activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells. J. Photochem. Photobiol. B, Biol. 69: 71-85.
3. Murray, D.A., et al. 2003. Lipopolysaccharide from the periodontal pathogen *Porphyromonas gingivalis* prevents apoptosis of HL60-derived neutrophils *in vitro*. Infect. Immun. 71: 7232-7235.
4. Nagatsuka, Y., et al. 2003. Carbohydrate-dependent signaling from the phosphatidylglucoside-based microdomain induces granulocytic differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA 100: 7454-7459.
5. Pantelic, M., et al. 2004. Retinoic acid treated HL60 cells express CEACAM1 (CD66A) and phagocytose *Neisseria gonorrhoeae*. FEMS Immunol. Med. Microbiol. 42: 261-266.
6. Jalal Hosseinimehr, S., et al. 2005. Activation of c-Kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of surviving in HL60 cells. J. Radiat. Res. 45: 557-561.
7. Liu, W.K., et al. 2005. Apoptotic activity of isomalabaricane triterpenes on human promyelocytic leukemia HL60 cells. Cancer Lett. 230: 102-110.
8. Yang, K.C., et al. 2006. Involvement of proapoptotic Bcl-2 family members in terbinafine-induced mitochondrial dysfunction and apoptosis in HL60 cells. Food Chem. Toxicol. 44: 214-226.
9. Yamazaki, Y., et al. 2006. Comprehensive analysis of monoclonal antibodies against detergent-insoluble membrane/lipid rafts of HL60 cells. J. Immunol. Methods 311: 106-116.

SOURCE

HL60 Antigen (IPO-M6) is a mouse monoclonal antibody raised against leukemia HL60 cell line of human origin.

PRODUCT

Each vial contains 200 µg IgG_1 in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

HL60 Antigen (IPO-M6) is available conjugated to either phycoerythrin (sc-59203 PE) or fluorescein (sc-59203 FITC), 200 µg/ml, for IF, IHC(P) and FCM.

APPLICATIONS

HL60 Antigen (IPO-M6) is recommended for detection of HL60 of human origin by flow cytometry (1 µg per 1 x 10^6 cells); non cross-reactive with B cell lines Daudi, PHS, NAMALWA, RPMI-1788 and T cell lines CCRF-HSB2, Jurkat and MOLT-4.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.